HUTCHMED Signs Global Development And License Deal With GSK For HMPL-A830

HUTCHMED said its subsidiary HUTCHMED (Shanghai) has reached an exclusive development and license agreement with a GlaxoSmithKline subsidiary for HMPL-A830, granting GSK rights to develop and commercialise the drug worldwide except in mainland China, Hong Kong, Macau and Taiwan. The clinical programme will initially focus on colorectal cancer, pancreatic cancer and lung cancer, according to ETNet. The deal includes a $110 million upfront payment, with potential development, regulatory and commercial milestone payments of up to $1.295 billion, plus royalties on net sales. HUTCHMED said the global first-in-class antibody-targeted conjugate candidate uses a highly selective, highly active KRAS inhibitor as the payload, linked to an EGFR antibody. HUTCHMED (Shanghai) will lead the global Phase I programme, which is expected to start in the second half of this year, while the GSK subsidiary will handle all subsequent clinical development and commercialisation outside the excluded markets.